Opus Genetics will present three abstracts at the ASCRS Annual Meeting in April 2026, including full results from Phase 3 studies evaluating phentolamine ophthalmic solution for presbyopia and mesopic vision disturbances. The company's partner Viatris is sponsoring an educational symposium on presbyopia management. Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases and advancing phentolamine as a small-molecule therapy.

Viatris trades at a significant discount despite generating a 13.5% free cash flow yield and $2.2 billion in annual FCF. With a $650 million cost savings program launching in 2026, six regulatory decisions expected, and two Phase 3 assets with blockbuster potential, the stock trades 17% below peer-average EV/EBITDA. The company's differentiated specialty pipeline leverages its unmatched global distribution infrastructure across 40 countries and 165 markets, positioning it for genuine inflection in 2026 with projected first year of top-line growth since formation.

Over 120 pharmaceutical companies are actively developing 140+ pipeline drugs for systemic lupus erythematosus (SLE), with approximately 30+ drugs in mid-stage development and 85+ in early stages. Key players include Roche, Biogen, Novartis, AbbVie, and Johnson & Johnson, with promising therapies targeting various mechanisms such as B cell inhibitors, JAK inhibitors, and TLR antagonists. Recent regulatory milestones include FDA Fast Track designation for nipocalimab and Breakthrough Therapy Designation for litifilimab.

Viatris Inc. (NASDAQ: VTRS) announced that its Board of Directors approved a 2026 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 per share, payable on March 18, 2026. This marks the sixth consecutive year the company has paid a dividend, demonstrating commitment to shareholder returns.

DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.

The systemic lupus erythematosus (SLE) market is projected to grow at a CAGR of 9.4% from 2025-2034, driven by rising disease prevalence, increased diagnostic awareness, and a robust pipeline of targeted therapies. The US market was valued at USD 2.8 billion in 2024 with approximately 529K diagnosed cases. Currently, only two FDA-approved therapies exist (BENLYSTA and SAPHNELO), but several promising drugs in mid-to-late stage development are expected to reshape the treatment landscape and address significant unmet medical needs.

Several S&P 500 stocks are trading at low forward price-to-earnings ratios, suggesting potential undervaluation and possible investment opportunities, with some stocks showing potential upside of up to 50%.

QSM Asset Management initiated a new $10.31 million position in Occidental Petroleum, acquiring 221,760 shares in Q3 2025, despite the stock's 18.77% decline over the past year.

The Trump administration will exclude imported generic drugs from potential tariffs, bringing relief to pharmaceutical companies and Indian drugmakers who supply nearly half of U.S. generic prescriptions.

The global epinephrine market is projected to grow from $2.77 billion in 2024 to $5.74 billion by 2032, driven by increasing cases of severe allergic reactions, technological advancements in auto-injectors, and rising awareness of anaphylaxis risks.

Saudi Arabia's generic drugs market is projected to grow from $4.05 billion in 2024 to $8.11 billion by 2033, driven by government cost-cutting initiatives, local manufacturing expansion, and increasing healthcare needs.

Theravance Biopharma reported Q2 2025 revenue of $26.2 million, driven by YUPELRI sales and a significant one-time gain from TRELEGY royalty asset sale. The company continues to focus on respiratory therapies and is advancing its ampreloxetine clinical program.